New cell therapy takes on deadly transplant complication
NCT ID NCT04118556
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This study tested a new treatment called DSC (donor stem cells) compared to the best available standard therapy for people with severe graft-versus-host disease (GVHD) after a stem cell transplant. GVHD happens when donor immune cells attack the patient's body, and this study focused on cases that didn't get better with steroids. The trial was stopped early, but researchers looked at safety and how many patients had a lasting response by day 56.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD,ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Copenhagen Univerity Hospital
Copenhagen, 2300, Denmark
-
Lund University Hospital
Lund, SE-221 85, Sweden
-
Oslo University Hospital
Oslo, NO-0424, Norway
-
Uppsala University Hospital
Uppsala, SE-75185, Sweden
Conditions
Explore the condition pages connected to this study.